A Study of T-DXd for the Treatment of Solid Tumors Harboring HER2 Activating Mutations
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Advanced Solid Tumors With HER2 Mutation,eg:Colorectal,Urothelial,Gastric, Hepatobiliary,Endometrial,Melanoma,Ovarian,Cervical,Salivary Gland,Pancreatic,Breast
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Masking Description: None (open-label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 120 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT04639219
- Collaborators
- Daiichi Sankyo Co., Ltd.
- Investigators
- Not Provided